1. Home
  2. GIB vs BIIB Comparison

GIB vs BIIB Comparison

Compare GIB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CGI Inc.

GIB

CGI Inc.

HOLD

Current Price

$92.37

Market Cap

20.3B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$176.11

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIB
BIIB
Founded
1976
1978
Country
Canada
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.3B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
GIB
BIIB
Price
$92.37
$176.11
Analyst Decision
Hold
Buy
Analyst Count
3
22
Target Price
$117.00
$177.40
AVG Volume (30 Days)
312.3K
2.3M
Earning Date
01-28-2026
02-11-2026
Dividend Yield
0.48%
N/A
EPS Growth
0.55
N/A
EPS
5.28
10.97
Revenue
$11,424,213,683.00
$10,065,900,000.00
Revenue This Year
$8.52
$3.58
Revenue Next Year
$3.31
N/A
P/E Ratio
$16.85
$16.04
Revenue Growth
8.43
4.77
52 Week Low
$84.00
$110.04
52 Week High
$122.79
$185.17

Technical Indicators

Market Signals
Indicator
GIB
BIIB
Relative Strength Index (RSI) 57.21 56.12
Support Level $88.10 $175.00
Resistance Level $94.52 $178.46
Average True Range (ATR) 1.49 3.90
MACD 0.01 -0.52
Stochastic Oscillator 66.51 61.73

Price Performance

Historical Comparison
GIB
BIIB

About GIB CGI Inc.

CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: